An anti-CSPG4 IgG1 monoclonal antibody has been reported to increase macrophage recruitment in a fully humanized mouse model of melanoma,118 and repeated administration of an anti-CSPG4 IgE monoclonal antibody therapy is well tolerated in immunocompetent animal models.133 The exact effect of anti-CSPG4 mAbs on macrophages remains unknown but warrants exploration, since polarizing TAMs and enhancing their antitumor properties may be a potential mechanism by which anti-CSPG4 can exert therapeutic effects. The gene discussed is CSPG4; the disease is melanoma.